Use this url to cite publication: https://hdl.handle.net/20.500.12512/96533
Options
Anti-N-methyl-D-aspartate receptor encephalitis: do early diagnosis and treatment improve outcomes? / Dambrauskienė Milda, Endzinienė Milda, Vaičienė-Magistris Nerija, Gurskis Vaidotas
Type of publication
Konferencijų tezės nerecenzuojamame leidinyje / Conference theses in non-peer-reviewed publication (T2)
Title
Anti-N-methyl-D-aspartate receptor encephalitis: do early diagnosis and treatment improve outcomes? / Dambrauskienė Milda, Endzinienė Milda, Vaičienė-Magistris Nerija, Gurskis Vaidotas
Publisher (trusted)
Baltic Child Neurology Association (BCNA) |
Date Issued
Date Issued |
---|
2017-05-18 |
Extent
p. 11-11.
Is part of
14th conference of the Baltic Child Neurology Association (BCNA) : May 18-20, 2017, Riga, Latvia : Program and abstracts / Baltic Child Neurology Association (BCNA). Riga : Baltic Child Neurology Association (BCNA), 2017.
Version
Originalus / Original
Series/Report no.
Oral presentations. Inflammatory diseases.
Field of Science
Keywords
Abstract
Background: Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis was described in 2007, and previously thought to be a rare entity. Now it is recognized as the main cause of an antibodymediated encephalitis, responsive to immunotherapy. First-line immunotherapy includes steroids, intravenous immunoglobulin, and plasmapheresis. Second line therapy includes rituximab, cyclophosphamide, or their combination. A proteasome inhibitor bortezomib has recently been described as a promising drug for therapy-refractory cases. Researchers agree that early and aggressive imunotherapy may affect outcomes. Other prognostic factors include patient's age, gender, stay in intensive care unit (ICU), and need for second-line therapy. Aim. To present a case of severe autoimmune encephalitis, to review pathogenesis, clinical presentation, diagnosis, treatment, and prognostic factors of anti-NMDAR encephalitis in pediatric population. Case report. The first patient in our hospital was diagnosed with anti-NMDAR encephalitis five years ago and search for diagnosis took more than two years. He was treated with first-line therapy, as well as the other patients diagnosed as having autoimmune encephalitis. We report a recent case of 3-year-old boy who presented with focal seizures, behavioural changes, psychosis, and sleep disorder. Later he developed hyperkinesis, autonomic dysfunction, and impaired consciousness. MRI revealed severe brain atrophy. Treatment based on clinical diagnosis was started immediately, as the positive answer for serum anti-NMDAR antibodies was received three weeks later. The patient stayed in ICU for 4 months, despite early diagnosis, and intensive immunotherapy. [...].
Type of document
type::text::conference output::conference proceedings::conference paper
Other Identifier(s)
(LSMU ALMA)990000938630107106
Coverage Spatial
Latvija / Latvia (LV)
Language
Anglų / English (en)
Affiliation(s)